160369-77-7

Fomivirsen Sodium was launched as Vitravene in the US and is indicated for the local treatment of cytomegalovirus (CMV)-induced retinitis in AIDS patients. It consists of a phosphorothioate oligonucleotide (PS) comprised of a sequence of 21 nucleotides. Fomivirsen is synthesized using solid-phase phosphoramidite chemistry. Fomivirsen inhibits human CMV replication by a antisense mechanism : it targets an immediate early mRNA of cytomegalovirus, inhibiting the expression of two regulatory proteins. Fomivirsen was the most advanced first-generation PS drug candidate in human clinical trials and was the first agent based on antisense technology to reach the market. In normal human dermal fibroblast cells, Fomivirsen inhibited AD169 human CMV replication by more than 90%, at a concentration of 5μM ; it showed greater hCMV replication inhibitor properties than ganciclovir in several experimental models.

Isis Pharmaceuticals (US)

Fomivirsen (ISIS-2922) sodium is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen sodium is an antiviral agent that is used cytomegalovirus retinitis (CMV) research, incluiding in AIDs. Fomivirsen sodium binds to and degrades the mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation[1][2].

Vitravene

Store at -20°C

[1] M D de Smet, et al. Fomivirsen- a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm. 1999 Dec;7(3-4):189-98. DOI:10.1076/ocii.7.3.189.4007
[2] Anna Kilanowska, et al. In vivo and in vitro studies of antisense oligonucleotides – a review. (Review Article)?RSC Adv., 2020,?10, 34501-34516 DOI:10.1039/d0ra04978f